Kitasato Institute, Meiji Eye Ivermectin Derivative Use for Post-COVID-19 Symptoms Too

Daikichiro Kobayashi, President of Meiji Seika Pharma (fourth left) and Hirosuke Kobayashi, Chairperson of the Kitasato Institute (fifth left) Ivermectin derivatives might turn into breakthrough therapies for COVID-19 with their potential to treat post viral symptoms as well, an official...read more